ROS1 Targeted Therapies: Current Status

Christine M. Azelby,Mandy R. Sakamoto,Daniel W. Bowles

DOI: https://doi.org/10.1007/s11912-021-01078-y

2021-06-14

Current Oncology Reports

Abstract:Molecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC.

oncology

What problem does this paper attempt to address?

ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals

Nathaniel J Myall,Millie Das

DOI: https://doi.org/10.1016/j.currproblcancer.2024.101133

2024-09-10

Abstract:Rearrangements involving the ROS1 gene are infrequent in non-small cell lung cancer (NSCLC) but represent an important targetable driver alteration. Occurring most commonly in patients with adenocarcinoma who have a light or never smoking history, ROS1 rearrangements can be identified by either fluorescence in-situ hybridization (FISH) or next-generation sequencing techniques. Multiple tyrosine kinase inhibitors (TKIs) are now available for the effective treatment of ROS1-rearranged NSCLC in the metastatic setting including crizotinib, entrectinib, and repotrectinib as first-line therapy options. In addition, newer targeted therapies with increased selectivity for ROS1 over other targets are also emerging. As treatment of the disease continues to evolve, understanding the clinical course of patients with ROS1-rearranged NSCLC as well as the data supporting the latest therapy options is key to timely, effective, and longitudinal care.
Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Shizhe Li,He Zhang,Ting Chen,Xiaowen Zhang,Guanning Shang

DOI: https://doi.org/10.1002/cam4.7201

IF: 4.711

2024-04-19

Cancer Medicine

Abstract:This study searched for relevant articles on the mechanism and clinical application of the ROS1 gene in recent years, systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors, and prospected the future of ROS1 targeted therapy to provide new ideas for clinical application and treatment. We believe that our study makes a significant contribution to the literature because our review revealed the following findings: the proto‐oncogene ROS1 is mostly expressed in malignant tumours, such as non‐small cell lung cancer (NSCLC). Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC. At the same time, the efficacy of other tyrosine kinase inhibitors (TKIs) for NSCLC and other malignancies has not been ascertained as they are still being tested in clinical trials. There is no standard effective treatment for adverse events or resistance to ROS1‐targeted therapy. Finally, next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis owing to their high affinity, but with a greater incidence of adverse effects. Background The proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next‐generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage. Method In this study, we searched relevant articles reporting the mechanism and clinical application of ROS1 in recent years; systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors; and provided perspectives for the future of ROS1‐targeted therapy. Results ROS1 is most expressed in malignant tumours. Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC, the efficacy of other TKIs for NSCLC and other malignancies has not been ascertained. There is no effective standard treatment for adverse events or resistance to ROS1‐targeted therapy. Next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis, but with a greater incidence of adverse effects. Conclusions Further research on next‐generation TKIs regarding the localization of ROS1 and its fusion partners, binding sites for targeted drugs, and coadministration with other drugs is required. The correlation between TKIs and chemotherapy or immunotherapy in clinical practice requires further study.

oncology
Progress of Non-Small-cell Lung Cancer with ROS1 Rearrangement

Xin Yang,Zhe Tang,Jing Li,Jizong Jiang,Yue Liu

DOI: https://doi.org/10.3389/fmolb.2023.1238093

IF: 6.113

2023-01-01

Frontiers in Molecular Biosciences

Abstract:ROS1 rearrangement is found in 0.9%–2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1 -positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.
Advances and future directions in ROS1 fusion-positive lung cancer

Mary C Boulanger,Jaime L Schneider,Jessica J Lin

DOI: https://doi.org/10.1093/oncolo/oyae205

2024-08-23

Abstract:ROS1 gene fusions are an established oncogenic driver comprising 1%-2% of non-small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small-molecule tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape of metastatic ROS1 fusion-positive (ROS1+) NSCLC and transformed outcomes for patients. The preferred Food and Drug Administration-approved first-line therapies include crizotinib, entrectinib, and repotrectinib, and currently, selection amongst these options requires consideration of the systemic and CNS efficacy, tolerability, and access to therapy. Of note, resistance to ROS1 TKIs invariably develops, limiting the clinical benefit of these agents and leading to disease relapse. Progress in understanding the molecular mechanisms of resistance has enabled the development of numerous next-generation ROS1 TKIs, which achieve broader coverage of ROS1 resistance mutations and superior CNS penetration than first-generation TKIs, as well as other therapeutic strategies to address TKI resistance. The approach to subsequent therapy depends on the pace and pattern of progressive disease on the initial ROS1 TKI and, if known, the mechanisms of TKI resistance. Herein, we describe a practical approach for the selection of initial and subsequent therapies for metastatic ROS1+ NSCLC based on these clinical considerations. Additionally, we explore the evolving evidence for the optimal treatment of earlier-stage, non-metastatic ROS1+ NSCLC, while, in parallel, highlighting future research directions with the goal of continuing to build on the tremendous progress in the management of ROS1+ NSCLC and ultimately improving the longevity and well-being of people living with this disease.
Progress of non-small-cell lung cancer with <i>ROS1</i> rearrangement

Xin Yang,Zhe Tang,Jing Li,Jizong Jiang,Yue Liu

DOI: https://doi.org/10.3389/fmolb.2023.1238093

IF: 6.113

2023-01-01

Frontiers in Molecular Biosciences

Abstract:ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1-positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.
Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: a Case Report and Review of the Literature

You-cai Zhu,Chun-wei Xu,Xiao-qian Ye,Man-xiang Yin,Jin-xian Zhang,Kai-qi Du,Zhi-hao Zhang,Jian Hu

DOI: https://doi.org/10.2147/ott.s109415

IF: 4

2016-01-01

OncoTargets and Therapy

Abstract:ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation.
An Updated Patent Review of Small-Molecule ROS1 Kinase Inhibitors (2015–2021)

Meng Li,Jintian Dai,Mudan Wei,Qingshan Pan,Wufu Zhu

DOI: https://doi.org/10.1080/13543776.2022.2058872

2022-01-01

Expert Opinion on Therapeutic Patents

Abstract:C-ros oncogene 1 (ROS1) is the sole member of the ROS1 receptor tyrosine kinase (ROS1-RTK) family, which is involved in the formation of non-small cell lung cancer (NSCLC), gastric adenocarcinoma, colorectal cancer, and other malignant tumors. At present, only crizotinib was approved for the treatment of advanced ROS1-positive NSCLC, and there have been reports of ROS1 mutations resulting in drug resistance. Consequently, it is necessary to develop new generations of inhibitors to overcome the existing problems.This review summarizes the inhibitors with ROS1 inhibitory activity which are undergoing clinical trials and recent advances in patented ROS1 small molecular inhibitors from 2015 to 2021.ROS1 rearrangements have been found in approximately 1%-2% of patients with NSCLC. Since the approval of crizotinib as multi-targeted ALK/MET/ROS1 kinase inhibitor for ALK-mutated NSCLC therapy, the researchers are focusing on ROS1-mutated tumors, especially NSCLC. However, drug-resistant mutations have already been found in clinical application. Therefore, it is still urgent to develop new generation of ROS1 inhibitors.
Recent Advances in the Development of Dual ALK/ROS1 Inhibitors for Non-Small Cell Lung Cancer Therapy.

Yingxue Li,Yanna Lv,Cheng Zhang,Binyu Fu,Yue Liu,Jinxing Hu

DOI: https://doi.org/10.1016/j.ejmech.2023.115477

IF: 7.088

2023-01-01

European Journal of Medicinal Chemistry

Abstract:As a member of the insulin-receptor superfamily, ALK plays an important role in regulating the growth, proliferation, and survival of cells. ROS1 is highly homologous with ALK, and can also regulate normal physiological activities of cells. The overexpression of both is closely related to the development and metastasis of tumors. Therefore, ALK and ROS1 may serve as important therapeutic targets in non-small cell lung cancer (NSCLC). Clinically, many ALK inhibitors have shown powerful therapeutic efficacy in ALK and ROS1-positive NSCLC patients. However, after some time, patients inevitably develop drug resistance, leading to treatment failure. There are no significant drug breakthroughs in solving the problem of drug-resistant mutations. In this review, we summarize the chemical structural features of several novel dual ALK/ROS1 inhibitors, their inhibitory effect on ALK and ROS1 kinases, and future treatment strategies for patients with ALK and ROS1 inhibitor-resistant mutations.
Ros1 Rearrangements Define A Unique Molecular Class of Lung Cancers

Kristin Bergethon,Alice T. Shaw,Sai-Hong Ignatius Ou,Ryohei Katayama,Christine M. Lovly,Nerina T. McDonald,Pierre P. Massion,Christina Siwak-Tapp,Adriana Gonzalez,Rong Fang,Eugene J. Mark,Julie M. Batten,Haiquan Chen,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,David P. Carbone,Hongbin Ji,Jeffrey A. Engelman,Mari Mino-Kenudson,William Pao,A. John Iafrate

DOI: https://doi.org/10.1200/jco.2011.35.6345

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:PurposeChromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs). Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement.Patients and MethodsUsing a ROS1 fluorescent in situ hybridization (FISH) assay, we screened 1,073 patients with NSCLC and correlated ROS1 rearrangement status with clinical characteristics, overall survival, and when available, ALK rearrangement status. In vitro studies assessed the responsiveness of cells with ROS1 rearrangement to the tyrosine kinase inhibitor crizotinib. The clinical response of one patient with ROS1-rearranged NSCLC to crizotinib was investigated as part of an expanded phase I cohort.ResultsOf 1,073 tumors screened, 18 (1.7%) were ROS1 rearranged by FISH, and 31 (2.9%) were ALK rearranged. Compared with the ROS1-negative group, patients with ROS1 rearrangements were significantly younger and more likely to be never-smokers (each P < .001). All of the ROS1-positive tumors were adenocarcinomas, with a tendency toward higher grade. ROS1-positive and-negative groups showed no difference in overall survival. The HCC78 ROS1-rearranged NSCLC cell line and 293 cells transfected with CD74-ROS1 showed evidence of sensitivity to crizotinib. The patient treated with crizotinib showed tumor shrinkage, with a near complete response.ConclusionROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib shows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC. J Clin Oncol 30: 863-870. (C) 2012 by American Society of Clinical Oncology
Recent progress in targeted therapy for non-small cell lung cancer

Yajun Lin,Yanxia Xiao,Pu Liu,Jie Wei,Xin Zhang,Jun Guo

DOI: https://doi.org/10.3389/fphar.2023.1125547

IF: 5.6

2023-02-22

Frontiers in Pharmacology

Abstract:The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people's health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes.

pharmacology & pharmacy
Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Hang‐Ping Yao,Sreedhar Reddy Suthe,Xiangmin Tong,Ming-Hai Wang

DOI: https://doi.org/10.1177/1758835920920069

2020-01-01

Therapeutic Advances in Medical Oncology

Abstract:The recepteur d’origine nantais (RON) receptor tyrosine kinase, belonging to the mesenchymal-to-epithelial transition proto-oncogene family, has been implicated in the pathogenesis of cancers derived from the colon, lung, breast, and pancreas. These findings lay the foundation for targeting RON for cancer treatment. However, development of RON-targeted therapeutics has not gained sufficient attention for the last decade. Although therapeutic monoclonal antibodies (TMABs) targeting RON have been validated in preclinical studies, results from clinical trials have met with limited success. This outcome diminishes pharmaceutical enthusiasm for further development of RON-targeted therapeutics. Recently, antibody–drug conjugates (ADCs) targeting RON have drawn special attention owing to their increased therapeutic activity. The rationale for developing anti-RON ADCs is based on the observation that cancer cells are not sufficiently addicted to RON signaling for survival. Thus, TMAB-mediated inhibition of RON signaling is ineffective for clinical application. In contrast, anti-RON ADCs combine a target-specific antibody with potent cytotoxins for cancer cell killing. This approach not only overcomes the shortcomings in TMAB-targeted therapies but also holds the promise for advancing anti-RON ADCs into clinical trials. In this review, we discuss the latest advancements in the development of anti-RON ADCs for targeted cancer therapy including drug conjugation profile, pharmacokinetic properties, cytotoxic effect in vitro, efficacy in tumor models, and toxicological activities in primates.
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Quincy S. Chu

DOI: https://doi.org/10.1177/1758835919895756

2020-01-01

Therapeutic Advances in Medical Oncology

Abstract:The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.

oncology
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Hang-Ping Yao,Sreedhar Reddy Suthe,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1177/1758835920920069

2020-01-01

Therapeutic Advances in Medical Oncology

Abstract:The recepteur d'origine nantais (RON) receptor tyrosine kinase, belonging to the mesenchymal-to-epithelial transition proto-oncogene family, has been implicated in the pathogenesis of cancers derived from the colon, lung, breast, and pancreas. These findings lay the foundation for targeting RON for cancer treatment. However, development of RON-targeted therapeutics has not gained sufficient attention for the last decade. Although therapeutic monoclonal antibodies (TMABs) targeting RON have been validated in preclinical studies, results from clinical trials have met with limited success. This outcome diminishes pharmaceutical enthusiasm for further development of RON-targeted therapeutics. Recently, antibody-drug conjugates (ADCs) targeting RON have drawn special attention owing to their increased therapeutic activity. The rationale for developing anti-RON ADCs is based on the observation that cancer cells are not sufficiently addicted to RON signaling for survival. Thus, TMAB-mediated inhibition of RON signaling is ineffective for clinical application. In contrast, anti-RON ADCs combine a target-specific antibody with potent cytotoxins for cancer cell killing. This approach not only overcomes the shortcomings in TMAB-targeted therapies but also holds the promise for advancing anti-RON ADCs into clinical trials. In this review, we discuss the latest advancements in the development of anti-RON ADCs for targeted cancer therapy including drug conjugation profile, pharmacokinetic properties, cytotoxic effect in vitro, efficacy in tumor models, and toxicological activities in primates.
Targeting MET in NSCLC: An Ever-Expanding Territory

Ying Han,Yinghui Yu,Da Miao,Mo Zhou,Jing Zhao,Zhehua Shao,Rui Jin,Xiuning Le,Wen Li,Yang Xia

DOI: https://doi.org/10.1016/j.jtocrr.2023.100630

2024-01-03

Abstract:MET protooncogene (MET) alterations are known driver oncogenes in NSCLC. Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody-drug conjugates now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers. Although clinical agents are currently available and numerous other options are in development, particular challenges in the field require attention. For example, the therapeutic efficacy of each drug remains unsatisfactory, and concomitantly, the resistance mechanisms are not fully understood. Thus, there is an urgent need for optimal drug sequencing and combinations, along with a thorough understanding of treatment resistance. In this review, we describe the current landscape of pertinent clinical trials focusing on MET-targeted strategies and discuss future developmental directions in this rapidly expanding field.
Targeting MET in Non-Small Cell Lung Cancer: an Ever-Expanding Territory

Ying Han,Yinghui Yu,Da Miao,Mo Zhou,Jing Zhao,Zhehua Shao,Rui Jin,Xiuning Le,Wen Li,Yang Xia

DOI: https://doi.org/10.1016/j.jtocrr.2023.100630

2024-01-01

JTO Clinical and Research Reports

Abstract:MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody–drug conjugates, now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers. Although clinical agents are currently available and numerous other options are in development, particular challenges in the field require attention. For example, the therapeutic efficacy of each drug remains unsatisfactory, and concomitantly, the resistance mechanisms are not fully understood. Thus, there is an urgent need for optimal drug sequencing and combinations, along with a thorough understanding of treatment resistance. In this review, we describe the current landscape of pertinent clinical trials focusing on MET-targeted strategies and discuss future developmental directions in this rapidly expanding field.
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Sara Elena Rebuzzi,Lodovica Zullo,Giovanni Rossi,Massimiliano Grassi,Veronica Murianni,Marco Tagliamento,Arsela Prelaj,Simona Coco,Luca Longo,Maria Giovanna Dal Bello,Angela Alama,Chiara Dellepiane,Elisa Bennicelli,Umberto Malapelle,Carlo Genova

DOI: https://doi.org/10.3390/ijms22052625

IF: 5.6

2021-03-05

International Journal of Molecular Sciences

Abstract:In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros oncogene 1 (ROS1), and V-raf murine sarcoma viral oncogene homolog B (BRAF) have been approved and are currently used in clinical practice. However, other promising molecular drivers are rapidly emerging as therapeutic targets. This review aims to cover the molecular alterations with a potential clinical impact in NSCLC, including amplifications or mutations of the mesenchymal–epithelial transition factor (MET), fusions of rearranged during transfection (RET), rearrangements of the neurotrophic tyrosine kinase (NTRK) genes, mutations of the Kirsten rat sarcoma viral oncogene (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), as well as amplifications or mutations of human epidermal growth factor receptor 2 (HER2). Additionally, we summarized the current status of targeted agents under investigation for such alterations. This revision of the current literature on emerging molecular targets is needed as the evolving knowledge on novel actionable oncogenic drivers and targeted agents is expected to increase the proportion of patients who will benefit from tailored therapeutic approaches.

biochemistry & molecular biology,chemistry, multidisciplinary
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Urska Janzic,Natalie Maimon Rabinovich,Walid Shalata,Waleed Kian,Katarzyna Szymczak,Rafal Dziadziuszko,Marko Jakopovic,Giannis Mountzios,Adam Pluzanski,Antonio Araujo,Andriani Charpidou,Sameh Daher,Abed Agbarya

DOI: https://doi.org/10.3390/curroncol31080326

2024-07-30

Abstract:ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC patients, diagnosed with advanced metastatic disease, were included. Molecular profiling using either FISH/CISH or NGS was performed on tissue samples. Twenty-eight patients were treated with crizotinib, while fourteen patients were administered newer drugs (entrectinib, repotrectinib) and seven patients received platinum-doublet chemotherapy in a first-line setting. Overall response rate and disease control rate for the crizotinib and entrectinb/repotrectinib cohort were 68% and 82% vs. 86% and 93%, respectively. Median progression free survival was 1.6 years (95% CI 1.15-2.215) for the crizotinib treatment vs. 2.35 years for the entrectinib/repotrectinib cohort (95% CI 1.19-3.52). Central nervous system progression was noted in 20% and 25% of the crizotinib and entrectinib/repotrectinib cohorts, respectively. This multi-center study presents real-world treatment patterns of ROS1 NSCLC population, indicating that crizotinib exhibited comparable results to entrectinib/repotrectinib in a first-line setting, although both response rate and survival was numerically longer with treatment with newer agents.
Emerging Targets in Non-Small Cell Lung Cancer

Louisa Liu,Joshua Soler,Karen L. Reckamp,Kamya Sankar

DOI: https://doi.org/10.3390/ijms251810046

IF: 5.6

2024-09-19

International Journal of Molecular Sciences

Abstract:Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in advanced NSCLC, elaborating on their clinical characteristics and specific mechanisms and molecular pathways for which targeted treatments are currently available. Additionally, we present an aggregate of ongoing clinical trials investigating the available treatment options targeting such alterations, in addition to their current recruitment status and preliminary efficacy data. These advancements may guide further research endeavors and inform future treatment strategies to improve the management of and transform outcomes for patients with advanced NSCLC.

biochemistry & molecular biology,chemistry, multidisciplinary
New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

R. Cervera,Yolanda Lage,Ana Gómez Rueda,Elena Corral de la Fuente,M. Olmedo,L. Cabezón-Gutiérrez,X. Mielgo-Rubio,F. Couñago,J. Trujillo

DOI: https://doi.org/10.5306/wjco.v13.i4.276

2022-04-24

World Journal of Clinical Oncology

Abstract:The 2004 discovery of EGFR mutations, followed by ALK rearrangements, ushered in a targeted therapy era for advanced non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting gene alterations have substantially improved survival and quality of life for patients with NSCLC. In the last decade, rearrangements of the ROS1 oncogene have been incorporated into healthcare practice that are applicable to another small subgroup of patients who benefit from similar targeted strategies. Recent genome studies of lung adenocarcinoma have identified other possible therapeutic targets, including RET, NTRK fusions, c-MET alterations, and activating mutations in KRAS, BRAF, and HER2, all with frequencies greater than 1%. Lung cancers harbouring these genome changes can potentially be treated with agents approved for other indications or under clinical development. This review updates the therapeutic arsenal that especially targets those genes.

Biology,Medicine
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Zixi Wang,Yurou Xing,Bingjie Li,Xiaoyu Li,Bin Liu,Yongsheng Wang

DOI: https://doi.org/10.1186/s43556-022-00107-x

2022-12-13

Molecular Biomedicine

Abstract:Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in 2004 represented the beginning of the precision medicine era for this refractory disease. This great progress benefits from the identification of driver gene mutations, and after that, conventional and new technologies such as NGS further illustrated part of the complex molecular pathways of NSCLC. More targetable driver gene mutation identification in NSCLC patients greatly promoted the development of targeted therapy and provided great help for patient outcomes including significantly improved survival time and quality of life. Herein, we review the literature and ongoing clinical trials of NSCLC targeted therapy to address the molecular pathways and targeted intervention progress in NSCLC. In addition, the mutations in EGFR gene, ALK rearrangements, and KRAS mutations in the main sections, and the less common molecular alterations in MET, HER2, BRAF, ROS1, RET, and NTRK are discussed. The main resistance mechanisms of each targeted oncogene are highlighted to demonstrate the current dilemma of targeted therapy in NSCLC. Moreover, we discuss potential therapies to overcome the challenges of drug resistance. In this review, we manage to display the current landscape of targetable therapeutic patterns in NSCLC in this era of precision medicine.

ROS1 Targeted Therapies: Current Status

ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Progress of Non-Small-cell Lung Cancer with ROS1 Rearrangement

Advances and future directions in ROS1 fusion-positive lung cancer

Progress of non-small-cell lung cancer with <i>ROS1</i> rearrangement

Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: a Case Report and Review of the Literature

An Updated Patent Review of Small-Molecule ROS1 Kinase Inhibitors (2015–2021)

Recent Advances in the Development of Dual ALK/ROS1 Inhibitors for Non-Small Cell Lung Cancer Therapy.

Ros1 Rearrangements Define A Unique Molecular Class of Lung Cancers

Recent progress in targeted therapy for non-small cell lung cancer

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Targeting MET in NSCLC: An Ever-Expanding Territory

Targeting MET in Non-Small Cell Lung Cancer: an Ever-Expanding Territory

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Emerging Targets in Non-Small Cell Lung Cancer

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer